thymine has been researched along with Lung Neoplasms in 21 studies
Lung Neoplasms: Tumors or cancer of the LUNG.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The possibility of interstitial pneumonitis should always be considered when a patient develops a fever and respiratory disorder during treatment containing TAS-102." | 1.48 | [A Case of Interstitial Pneumonitis Induced by TAS-102 for Liver and Lung Metastasis of Colorectal Cancer]. ( Hiramatsu, M; Imai, Y; Kobayashi, T; Kono, E; Sakane, J; Suzuki, Y; Tsunematsu, I, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (23.81) | 18.7374 |
| 1990's | 6 (28.57) | 18.2507 |
| 2000's | 3 (14.29) | 29.6817 |
| 2010's | 7 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Unseld, M | 1 |
| Drimmel, M | 1 |
| Siebenhüner, A | 1 |
| Gleiss, A | 1 |
| Bianconi, D | 1 |
| Kieler, M | 1 |
| Scheithauer, W | 1 |
| Winder, T | 1 |
| Prager, GW | 1 |
| Kono, E | 1 |
| Hiramatsu, M | 1 |
| Kobayashi, T | 1 |
| Tsunematsu, I | 1 |
| Imai, Y | 1 |
| Sakane, J | 1 |
| Suzuki, Y | 1 |
| Lee, SJ | 1 |
| Yeo, JS | 1 |
| Lee, HJ | 1 |
| Lee, EJ | 1 |
| Kim, SY | 1 |
| Jang, SJ | 1 |
| Lee, JJ | 1 |
| Ryu, JS | 1 |
| Moon, DH | 1 |
| Gao, P | 1 |
| Zhao, H | 1 |
| You, J | 1 |
| Jing, F | 1 |
| Hu, Y | 1 |
| Hasegawa, J | 1 |
| Noura, S | 1 |
| Hirota, M | 1 |
| Matsumura, T | 1 |
| Yasuyama, A | 1 |
| Takata, A | 1 |
| Koga, C | 1 |
| Murakami, M | 1 |
| Kameda, C | 1 |
| Oda, N | 1 |
| Kawabata, R | 1 |
| Morishima, H | 1 |
| Shimizu, J | 1 |
| Matsunami, N | 1 |
| Saito, T | 1 |
| Mitomi, H | 1 |
| Izumi, H | 1 |
| Suehara, Y | 1 |
| Okubo, T | 1 |
| Torigoe, T | 1 |
| Takagi, T | 1 |
| Kaneko, K | 1 |
| Sato, K | 1 |
| Matsumoto, T | 1 |
| Yao, T | 1 |
| Zheng, X | 1 |
| Duan, W | 1 |
| Xu, J | 1 |
| Nie, C | 1 |
| Yang, Z | 1 |
| Wang, H | 1 |
| Wang, W | 1 |
| Lu, D | 1 |
| Rodin, SN | 1 |
| Rodin, AS | 1 |
| Cohen, Y | 1 |
| Xing, M | 1 |
| Mambo, E | 1 |
| Guo, Z | 1 |
| Wu, G | 1 |
| Trink, B | 1 |
| Beller, U | 1 |
| Westra, WH | 1 |
| Ladenson, PW | 1 |
| Sidransky, D | 1 |
| ROGERS, S | 1 |
| Wang, YJ | 1 |
| Ho, YS | 1 |
| Lo, MJ | 1 |
| Lin, JK | 1 |
| Ronai, ZA | 1 |
| Gradia, S | 1 |
| Peterson, LA | 1 |
| Hecht, SS | 1 |
| Matsuda, A | 1 |
| Dan, A | 1 |
| Minakawa, N | 1 |
| Tregear, SJ | 1 |
| Okazaki, S | 1 |
| Sugimoto, Y | 1 |
| Sasaki, T | 1 |
| Shields, AF | 1 |
| Mankoff, D | 1 |
| Graham, MM | 1 |
| Zheng, M | 1 |
| Kozawa, SM | 1 |
| Link, JM | 1 |
| Krohn, KA | 1 |
| Chen, H | 1 |
| Lum, A | 1 |
| Seifried, A | 1 |
| Wilkens, LR | 1 |
| Le Marchand, L | 1 |
| Hainaut, P | 1 |
| Pfeifer, GP | 1 |
| Devereux, TR | 1 |
| Anderson, MW | 1 |
| Belinsky, SA | 1 |
| Wolberg, WH | 1 |
| Dvorák, O | 1 |
| Elis, J | 1 |
| Perlík, F | 1 |
| Kvícalová, M | 1 |
| Jandová, A | 1 |
| Skoda, V | 1 |
| Kafka, V | 1 |
| Platonova, GM | 1 |
| Pogosiants, EE | 1 |
| Kaye, AM | 1 |
| Trainin, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Trial of BAY 43-9006 (Sorafenib) and Bevacizumab in Refractory Solid Tumors With Biologic and Proteomic Analysis[NCT00095459] | Phase 1 | 57 participants (Actual) | Interventional | 2004-11-02 | Completed | ||
| A Phase II Study of Sorafenib and Bevacizumab in Epithelial Ovarian, Fallopian, and Peritoneal Cancer[NCT00436215] | Phase 2 | 55 participants (Actual) | Interventional | 2006-12-12 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module. (NCT00436215)
Timeframe: up to 28 months
| Intervention | Participants (Count of Participants) |
|---|---|
| BAY 43-9006 + Bevacizumab | 54 |
Progression free survival is defined by the number of weeks between the first day of treatment and the date of cancer progression. (NCT00436215)
Timeframe: up to 28 months
| Intervention | Weeks (Mean) |
|---|---|
| BAY 43-9006 + Bevacizumab | 26 |
Clinical response rate is defined as the percentage of participants with a complete response (CR) or partial response (PR) per the Response Evaluation Criteria in Solid Tumors (RECIST). CR is disappearance of all target lesions. PR is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. Progressive disease (PD) is a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. Stable disease (SD) is neither sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started lasting at least 6 months. (NCT00436215)
Timeframe: patients were followed for a median of 18 weeks (range 1-116 weeks)
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Complete Response | Partial Response | Progressive Disease | Stable Disease | |
| BAY 43-9006 + Bevacizumab | 0 | 19 | 21 | 60 |
1 review available for thymine and Lung Neoplasms
| Article | Year |
|---|---|
Association between interleukin-8 -251A/T polymorphism and risk of lung cancer: a meta-analysis.
Topics: Adenine; Asian People; Computational Biology; Databases, Bibliographic; Genetic Association Studies; | 2014 |
1 trial available for thymine and Lung Neoplasms
| Article | Year |
|---|---|
A controlled clinical trial with the cytostatic agent thyminalkylamine and its fluorinated derivative on advanced ovarian tumours.
Topics: Alkylating Agents; Female; Fluorine; Hemodynamics; Humans; Leukocyte Count; Leukocytes; Lung Neoplas | 1971 |
19 other studies available for thymine and Lung Neoplasms
| Article | Year |
|---|---|
Optimizing Treatment Sequence for Late-line Metastatic Colorectal Cancer Patients Using Trifluridine/Tipiracil and Regorafenib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; | 2018 |
[A Case of Interstitial Pneumonitis Induced by TAS-102 for Liver and Lung Metastasis of Colorectal Cancer].
Topics: Aged; Drug Combinations; Humans; Liver Neoplasms; Lung Diseases, Interstitial; Lung Neoplasms; Male; | 2018 |
Thymidine phosphorylase influences [(18)F]fluorothymidine uptake in cancer cells and patients with non-small cell lung cancer.
Topics: Adult; Aged; Biological Transport; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dideoxynucleosi | 2014 |
[A Case of Metastatic Colorectal Cancer Refractory to Standard Chemotherapies Treated with TAS-102 with Bevacizumab].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Combined Modality Therapy; Drug Combina | 2016 |
A case of secondary malignant giant-cell tumor of bone with p53 mutation after long-term follow-up.
Topics: Adenocarcinoma; Arthrography; Base Sequence; Cell Transformation, Neoplastic; Cysteine; Femur; Fibro | 2011 |
Functionally significant nicotine acetylcholine receptor subunit α5 promoter haplotypes are associated with susceptibility to lung cancer in Chinese.
Topics: Adult; Aged; Asian People; Case-Control Studies; China; Cytosine; Female; Gene Deletion; Gene Freque | 2011 |
On the origin of p53 G:C --> T:A transversions in lung cancers.
Topics: Adenine; Chi-Square Distribution; Databases, Genetic; DNA Repair; Gene Frequency; Humans; Lung Neopl | 2002 |
BRAF mutation in papillary thyroid carcinoma.
Topics: Adenine; Carcinoma, Papillary; Case-Control Studies; Head and Neck Neoplasms; Humans; Lung Neoplasms | 2003 |
BRAF mutation in papillary thyroid carcinoma.
Topics: Adenine; Carcinoma, Papillary; Case-Control Studies; Head and Neck Neoplasms; Humans; Lung Neoplasms | 2003 |
BRAF mutation in papillary thyroid carcinoma.
Topics: Adenine; Carcinoma, Papillary; Case-Control Studies; Head and Neck Neoplasms; Humans; Lung Neoplasms | 2003 |
BRAF mutation in papillary thyroid carcinoma.
Topics: Adenine; Carcinoma, Papillary; Case-Control Studies; Head and Neck Neoplasms; Humans; Lung Neoplasms | 2003 |
Studies of the mechanism of action of urethane in initiating pulmonary adenomas in mice. II. Its relation to nucleic acid synthesis.
Topics: Adenine; Adenoma; Animals; DNA; Lung Neoplasms; Mice; Neoplasms; Nucleic Acids; Orotic Acid; Pyrimid | 1957 |
Oxidative modification of DNA bases in rat liver and lung during chemical carcinogenesis and aging.
Topics: 2-Acetylaminofluorene; Adenine; Aging; Animals; Antineoplastic Agents; Disease Models, Animal; DNA D | 1995 |
G to A transitions and G to T transversions in codon 12 of the Ki-ras oncogene isolated from mouse lung tumors induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and related DNA methylating and pyridyloxobutylating agents.
Topics: Adenine; Animals; Base Sequence; Carcinogens; Codon; Dimethylnitrosamine; DNA, Neoplasm; Female; Gen | 1993 |
Nucleosides and nucleotides. 123. Synthesis of 1-(2-deoxy-2-isocyano-beta-D-arabinofuranosyl)cytosine and related nucleosides as potential antitumor agents.
Topics: Animals; Antineoplastic Agents; Cytarabine; Deoxycytidine; Drug Stability; Humans; Isocyanates; Leuk | 1993 |
Analysis of 2-carbon-11-thymidine blood metabolites in PET imaging.
Topics: Carbon Dioxide; Carbon Radioisotopes; Chromatography, High Pressure Liquid; Humans; Lung Neoplasms; | 1996 |
Association of the NAD(P)H:quinone oxidoreductase 609C-->T polymorphism with a decreased lung cancer risk.
Topics: Alleles; Asian People; Case-Control Studies; Cytosine; Female; Genetic Variation; Genotype; Hawaii; | 1999 |
Patterns of p53 G-->T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke.
Topics: Case-Control Studies; Codon; DNA Damage; Guanine; Humans; Lung Neoplasms; Mutagens; Nicotiana; Plant | 2001 |
Role of ras protooncogene activation in the formation of spontaneous and nitrosamine-induced lung tumors in the resistant C3H mouse.
Topics: Animals; Base Sequence; Codon; Dimethylnitrosamine; DNA; Drug Resistance; Gene Expression Regulation | 1991 |
Response of DNA thymine synthesis in human tumor and normal tissue to 5-fluorouracil.
Topics: Breast Neoplasms; Carbon Isotopes; Chromatography, Paper; Colon; Colonic Neoplasms; Depression, Chem | 1972 |
[The effect of thymine on the development of adenomain the lungs of mice under the influence of urethane and N-hydroxyurethane].
Topics: Adenoma; Animals; Lung Neoplasms; Mice; Neoplasms, Experimental; Thymine; Urethane | 1969 |
Urethan carcinogenesis and nucleic acid metabolism: factors influencing lung adenoma induction.
Topics: Aminopterin; Animals; Lung Neoplasms; Mice; Neoplasms, Experimental; Nucleic Acids; Orotic Acid; Thy | 1966 |